XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

By J. Torgerson, J. Hauptman, M. Boldrin, L. Sjöström. Diabetes Care, 2004

1,973 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The metabolic syndrome. (2008, background): “In addition, a 4-yr randomized controlled study of orlistat showed a significant reduction in the progression to diabetes in high-risk individuals (590).”
Pharmacological management of obesity: an endocrine Society clinical practice guideline. (2015, background): “Orlistat blocks absorption of 25 to 30% of fat calories and is not appreciably absorbed systemically (28, 29).”
Metabolically Healthy Obesity (2020, background): “For example, orlistat treatment over 4 years (105) and liraglutide”
Meta-Analysis: Pharmacologic Treatment of Obesity (2005, background): “A recently published study has demonstrated efficacy and safety in a 4-year trial of orlistat (73).”